Zynerba Pharmaceuticals, Inc. (ZYNE)

NasdaqGM - NasdaqGM Real Time Price. Currency in USD

Add to watchlist

Visitors trend2W10W9M

1.3100

+0.0100

(+0.77%)

At close: 04:00PM EDT

1.2800

-0.03

(-2.29%)

After hours:

07:57PM EDT

Advertisement

Full screen

Trade prices are not sourced from all markets

Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies

Chart Events

Bullishpattern detected

Williams %R

View all chart patterns

Performance Outlook

Previous Close	1.3000
Open	1.3400
Bid	1.2800 x 1000
Ask	1.3400 x 900
Day's Range	1.2700 - 1.3500
52 Week Range	0.8360 - 4.6500
Volume	490,348
Avg. Volume	565,312

Market Cap	59.937M
Beta (5Y Monthly)	N/A
PE Ratio (TTM)	N/A
EPS (TTM)	-0.9620
Earnings Date	Nov 14, 2022 - Nov 18, 2022
Forward Dividend & Yield	N/A (N/A)
Ex-Dividend Date	N/A
1y Target Est	7.00

Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.

Fair Value

XX.XX

Overvalued

Subscribe to Yahoo Finance Plus to view Fair Value for ZYNE

View details

Research that delivers an independent perspective, consistent methodology and actionable insight

Related Research

Zynerba Pharmaceuticals, Inc.
Analyst Report: The Scotts Miracle-Gro CompanyScotts Miracle-Gro is the largest provider of gardening and lawncare products in the United States. The majority of the company's sales are to large retailers that include Home Depot, Lowe's, and Walmart. Scotts Miracle-Gro can sell its products at a higher price point than its competition because of a well-recognized portfolio of brands that include Miracle-Gro, Roundup, Ortho, Tomcat, and Scotts. Scotts is also the leading supplier of cannabis-growing equipment in North America through its Hawthorne business.
Rating
Fair Value
Economic Moat
10 days agoMorningstar

All

GlobeNewswire
Zynerba Pharmaceuticals Reports Second Quarter 2022 Financial Results and Operational Highlights
Enrollment continues in RECONNECT, a confirmatory pivotal Phase 3 trial of Zygel™ in patients with Fragile X syndrome (FXS); topline results expected second-half 2023 Announced positive topline results from Phase 2 trial of Zygel in patients with 22q11.2 deletion syndrome (22q) Company focusing resources on orphan neuropsychiatric disorders, FXS and 22q $62.5 million in cash and cash equivalents at June 30, 2022; Cash runway through the end of 2023 / early 2024 DEVON, Pa., Aug. 10, 2022 (GLOBE N
- Movie Theaters Plot Revival as Americans Show Up for Blockbusters
  The Wall Street Journal
- Imago BioSciences Reports Second Quarter 2022 Financial Results and Provides Recent Business Updates
  GlobeNewswire
GlobeNewswire
Zynerba Pharmaceuticals to Present In Person at the Canaccord Genuity 42nd Annual Growth Conference
DEVON, Pa., Aug. 03, 2022 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals, Inc. (Nasdaq: ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for orphan neuropsychiatric disorders, today announced that Armando Anido, Chairman and Chief Executive Officer of Zynerba Pharmaceuticals, will present an overview and update of the Company at the Canaccord Genuity 42nd Annual Growth Conference on Wednesday, August 10, 2022 at 9:00 a.m. ET at the InterContinental Boston
Simply Wall St.
We're Hopeful That Zynerba Pharmaceuticals (NASDAQ:ZYNE) Will Use Its Cash Wisely
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...